China · Delayed Price · Currency is CNY Evopoint Biosciences Company Description
Evopoint Biosciences Co., Ltd. operates as a biopharmaceutical company that offers therapies for patients with oncology and multidrug-resistant (MDR) infections in China.
It offers its three-core technology platforms, Small Molecule Drug Discovery Platform that uses multi-omics, functional screening, and a medicinal chemistry engine to create precision therapies for epigenetics, synthetic lethality, and MDR infections; Novel Antibody Discovery Platform which offers antibody therapeutics (e.g., ADCs, bispecifics, TCEs) to achieve precision and expanded therapeutic windows against refractory solid tumors like pancreatic and gastric cancer; and Targeted Protein Degradation Platform, a glue and ligase-mediated ubiquitin-dependent elimination platform.
The company also has various drugs in its pipeline including XNW4107 for HABP/VABP, XNW5004 for Lymphoma & Solid Tumor; XNW27011, XNW28012, XNW29016, and XNW34017 for solid tumor and XNW1011 for autoimmune diseases.
The company was formerly known as Suzhou Sinovent Pharmaceuticals Co., Ltd. The company was founded in 2017 and is based in Suzhou, China.
| Country | China |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 362 |
| CEO | Meijie Le |
Contact Details
Address: Biomedical Industrial Park Building 22 Suzhou, 215000 China | |
| Phone | 86 51 2891 62125 |
| Website | evopointbio.com |
Stock Details
| Ticker Symbol | 688837 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Meijie Le | Chief Executive Officer |
| Song Yun | Chief Financial Officer |